<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827592</url>
  </required_header>
  <id_info>
    <org_study_id>000079</org_study_id>
    <secondary_id>2012-005587-94</secondary_id>
    <nct_id>NCT01827592</nct_id>
  </id_info>
  <brief_title>26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation
      treated for 26 Weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present trial was designed to determine the efficacy and safety of elobixibat treatment
      (at both doses of 5 mg and 10 mg/day) compared to placebo treatment for 26-week Treatment
      Period in patients with chronic idiopathic constipation. Patients were followed-up for 2
      weeks after end of the Treatment Period.

      The assessment of primary and key secondary end points was done for patients who completed
      the first 12 weeks of Treatment Period. Incidence of Adverse Events (AEs) were reported till
      2 weeks after end of the treatment.

      The trial was early terminated due to a distribution issue with the trial medication.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to a distribution issue with the trial medication
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Complete Spontaneous Bowel Movement (CSBM) Response</measure>
    <time_frame>During the first 12 weeks</time_frame>
    <description>This outcome measured the percentage of patients who were CSBM responders. A CSBM responder was defined as a patient with ≥3 CSBMs per week and an increase of ≥1 CSBM per week from Baseline, for at least 9 of the 12 weeks in the 12-week Treatment Period, including at least 3 weeks during Weeks 9-12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of CSBM Response</measure>
    <time_frame>Within the first 24 hours of treatment initiation</time_frame>
    <description>This outcome measured the percentage of patients who had a CSBM within 24 hours after the first dose of treatment. A CSBM was defined as a spontaneous (occurring without laxative within the preceding 24 hours, including no rescue medication within the preceding 24 hours) bowel movement (as interpreted by the patient, with a beginning and an end, including single or multiple stools), accompanied by a patient reported sense of complete evacuation ('complete').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Frequency of Spontaneous Bowel Movements (SBMs)</measure>
    <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
    <description>The change from Baseline for the continuous variable was estimated using a repeated measures analysis of covariance (ANCOVA) model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Stool Consistency of SBMs</measure>
    <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
    <description>The stool consistency is measured using the seven-point ordinal Bristol Stool Form Scale (BSFS) score. The BSFS classifies human stool into seven types and points them accordingly.
Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid Types 1 and 2 indicate constipation, with 3 and 4 represents the ideal stool form (especially the latter), and 5, 6 and 7 tends towards diarrhoea .
For a given assessment week, the weekly stool consistency was defined as the sum of non-missing stool consistency score for SBMs during that week divided by the number of non-missing stool consistency score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Patient Assessment of Constipation - Quality of Life (PAC-QOL) Score Responder</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>This outcome measured the percentage of patients who were PAC-QOL score responder at 12-week of Treatment Period. A PAC-QOL score responder was defined as a patient with ≥50% reduction in total PAC-QOL score from Baseline at Week 12.
PAC-QOL is a 28-item questionnaire for psychometric assessment of disease-specific quality of life. The questionnaire is based on 5-point Likert scale; ranging from 0 [none of the time or not at all] to 4 [all of the time or extremely]). A lower score indicates a better Quality of Life. The PAC-QOL questionnaire is developed specifically for patients with constipation.
Total PAC-QOL score was averaged from the individual item score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Degree of Straining of SBMs</measure>
    <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
    <description>The degree of straining was measured using the five-point ordinal scale (1=Not at all, 2=A little bit, 3=A moderate amount, 4=A great deal, and 5=An extreme amount).
For a given assessment week, the weekly degree of straining was defined as the sum of non-missing straining score for SBMs during that week divided by the number of non-missing straining score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Abdominal Bloating Score</measure>
    <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
    <description>The abdominal bloating score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).
For a given assessment week, the weekly abdominal bloating score was defined as the sum of non-missing abdominal bloating score for SBMs during that week divided by the number of non-missing abdominal bloating score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Abdominal Discomfort Score</measure>
    <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
    <description>The abdominal discomfort score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).
For a given assessment week, the weekly abdominal discomfort score was defined as the sum of non-missing abdominal discomfort score for SBMs during that week divided by the number of non-missing abdominal discomfort score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Chronic Idiopathic Constipation</condition>
  <arm_group>
    <arm_group_label>EBX 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elobixibat 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBX 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elobixibat 5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLCBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elobixibat 10 mg</intervention_name>
    <description>Elobixibat 10 mg/day</description>
    <arm_group_label>EBX 10</arm_group_label>
    <other_name>A3309</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elobixibat 5 mg</intervention_name>
    <description>Elobixibat 5 mg/day</description>
    <arm_group_label>EBX 5</arm_group_label>
    <other_name>A3309</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>PLCBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥18.5 but &lt;35.0 kg/m^2

          -  Male or female ≥18 years of age

          -  Reports &lt;3 spontaneous Bowel movements (BM) per week and reports one or more of the
             following symptoms for the last 3 months with symptom onset at least 6 months before
             the Screening Visit or before starting chronic therapy with any laxative:

               1. Straining during at least 25% of defecations

               2. Lumpy or hard stools during at least 25% of defecations

               3. Sensation of incomplete evacuation during at least 25% of defecations

          -  Is ambulatory and community dwelling

          -  An initial colonoscopy is required if recommended by national guidelines

        Exclusion Criteria:

          -  Reports loose (mushy) or watery stools in the absence of any laxative intake in the
             form of a tablet, a suppository or an enema, or prohibited medicine for &gt;25% of BMs

          -  The patient reports a BSFS of 6 or 7 during the Pretreatment Period

          -  Has irritable bowel syndrome (IBS) with pain/discomfort as predominant symptoms

          -  Has a structural abnormality of the GI tract or a disease or condition that can affect
             Gastrointestinal (GI) motility

          -  Has a history of diverticulitis, chronic pancreatitis, active peptic ulcer disease
             (PUD) not adequately treated, ischaemic colitis, inflammatory bowel disease, laxative
             abuse, faecal impaction that required hospitalization or emergency treatment,
             pseudo-obstruction, megacolon, megarectum, bowel obstruction, descending perineum
             syndrome, ovarian cysts, endometriosis, solitary rectal ulcer syndrome, systemic
             sclerosis, pre-malignant colonic disease (e.g., familial adenomatous polyposis or
             hereditary non-polyposis colorectal cancer) or other forms of familial colorectal
             cancer.

          -  Has unexplained and clinically significant GI alarm signals (e.g., lower GI bleeding
             or heme-positive stool in the absence of known internal or external haemorrhoids,
             iron-deficiency anaemia, unexplained weight loss) or systemic signs of infection or
             colitis

          -  Has a potential central nervous system (CNS) cause of constipation (e.g., Parkinson's
             disease, spinal cord injury, multiple sclerosis)

          -  Has intestinal/rectal prolapse or other known pelvic floor dysfunction

          -  Commonly uses digital manoeuvres (perianal pressure or digital disimpaction) or
             vaginal splinting to facilitate the passage of a bowel movement

          -  Has a history of diabetic neuropathy

          -  Has a history of bariatric surgery for treatment of obesity; surgery to remove a
             segment of the GI tract; or surgery of the abdomen, pelvic or retroperitoneal area
             during the 6 months prior to Screening; or appendectomy or cholecystectomy 3 months
             prior to screening; or other major surgery 1 month prior to Screening

          -  Has a history of cancer with last date of proven disease activity/presence of
             malignancy within 5 years, except for adequately treated basal cell carcinoma of the
             skin, cervical dysplasia, or carcinoma in situ of the skin or the cervix

          -  Known human immunodeficiency virus (HIV) or Hepatitis B/C (HBV/HCV) infection

          -  Has a history of hospitalization for any psychiatric disorder, or any suicide attempt
             in the 2 years prior to Screening

          -  Is actively abusing alcohol or drugs or has a history of alcohol or drug abuse during
             the 6 months prior to Screening

          -  Is being treated for hypothyroidism, but the dose of medication has not been stable
             for at least 3 months at the time of Screening

          -  Is a pregnant, breast-feeding, or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G and L Research, LLC</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adobe Gastroenterology Research, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyline Research LLC</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GW Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stamford Therapeutics Consortium</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>In Vivo Clinical Research, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medsearch Professional Group, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Gastrointestinal Disorders</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research, LLC</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Hepatology Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jupiter Research Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Gastroenterology</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials, Inc.</name>
      <address>
        <city>Blackfoot</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSphere Medical Research Center, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAtlantic Medical Research Centers, Philip J. Bean Medical Center</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Gastroenterology Partners</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research of America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research, Inc.</name>
      <address>
        <city>Newington</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSC, Inc.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North American Partners in Pain Management</name>
      <address>
        <city>Valley Stream</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Digestive Health Associates, PA</name>
      <address>
        <city>Davidson</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Research Consultants of Greater Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Occupational Health</name>
      <address>
        <city>Groveport</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Digestive Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research Services, LLC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mainline Gastroenterology Associates</name>
      <address>
        <city>Souderton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastroenterology Group, PC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRK Medical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Gastroenterology Associates</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huisartspraktijk Jaak Mortelmans</name>
      <address>
        <city>Ham</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Sant André</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Escola Paulista de Medicina, Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Buhler Research Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maritime Medical Research Center</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prime Health Clinical Research Organization</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Clinical Research LLC</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhodin Recherche Clinique</name>
      <address>
        <city>DrummondvilleQC</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma Plus s.r.o.</name>
      <address>
        <city>Ceské Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologie, s. r. o.</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Valasske Mezirici a.s., Gastroenterologicka ambulance</name>
      <address>
        <city>Valasske Mezirici</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elbe Klinikum Stade - Buxtehude GmbH</name>
      <address>
        <city>Stade</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Charité, Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Israelitisches Krankenhaus Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Centre</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Szpital Kliniczny nr 5 im. Gen. Dyw. B. Szareckiego, Uniwersytetu Medycznego</name>
      <address>
        <city>Lódz</city>
        <state>Lodzkie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Opolu</name>
      <address>
        <city>Opole</city>
        <state>Opolskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne sw. Lukasza Sp. z o.o.</name>
      <address>
        <city>Czestochowa</city>
        <state>Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Care NZOZ</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomorski Uniwersytet Medyczny</name>
      <address>
        <city>Szczecin</city>
        <state>Zachodniopomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Clinical Trials</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boanerges Clinical Research</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research SA</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parklands Medical Centre</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boland Ethical Research Group</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memory Centre</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Langeberg Clinical Trials</name>
      <address>
        <city>Kraaifontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newtown Clinical Research Centre</name>
      <address>
        <city>Newtown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands Clinical Research Centre</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Durham and Darlington NHS Foundation Trust</name>
      <address>
        <city>Durham</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Manchester Clinical Research Centre</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tayside University Hospitals NHS Trust, Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Wales Clinical Research Centre</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <results_first_submitted>July 17, 2015</results_first_submitted>
  <results_first_submitted_qc>September 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2015</results_first_posted>
  <disposition_first_submitted>April 7, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 7, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 29, 2015</disposition_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The trial included a 4-week Screening Period and a 2-week Pretreatment Period prior to patient randomization to a 26-week Treatment Period. A total of 909 patients were screened in the trial and of these 533 patients were excluded due to screening failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EBX 10</title>
          <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till End of the Treatment (EoT) visit.</description>
        </group>
        <group group_id="P2">
          <title>EBX 5</title>
          <description>Elobixibat 5 mg/day as administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
        <group group_id="P3">
          <title>PLCBO</title>
          <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126">Randomized patients.</participants>
                <participants group_id="P2" count="126">Randomized patients.</participants>
                <participants group_id="P3" count="124">Randomized patients.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="125">1 patient withdrew consent before getting the treatment.</participants>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's substantial non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Others</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat population</population>
      <group_list>
        <group group_id="B1">
          <title>EBX 10</title>
          <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
        <group group_id="B2">
          <title>EBX 5</title>
          <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
        <group group_id="B3">
          <title>PLCBO</title>
          <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="124"/>
            <count group_id="B4" value="376"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="14.3"/>
                    <measurement group_id="B2" value="45.8" spread="14.1"/>
                    <measurement group_id="B3" value="46.1" spread="14.4"/>
                    <measurement group_id="B4" value="46.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weekly number of CSBM</title>
          <description>CSBM was defined as a spontaneous (occurring without laxative within the preceding 24 hours, including no rescue medication within the preceding 24 hours) bowel movement (as interpreted by the patient, with a beginning and an end, including single or multiple stools), accompanied by a patient reported sense of complete evacuation (‘complete’).
Baseline value for the number of CSBM per week was defined as the average of the numbers of CSBM per week for over the 2-week Pretreatment Period.</description>
          <units>CSBM per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.36" spread="0.66"/>
                    <measurement group_id="B2" value="0.44" spread="0.75"/>
                    <measurement group_id="B3" value="0.54" spread="0.82"/>
                    <measurement group_id="B4" value="0.45" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weekly number of SBM</title>
          <description>SBM was defined as a bowel movement that occurs in the absence of a laxative use or manual disimpaction.
Baseline value for the number of SBM was defined as the average of the numbers of SBM per week for over the 2-week Pretreatment Period.</description>
          <units>SBM per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.20" spread="1.34"/>
                    <measurement group_id="B2" value="2.13" spread="1.27"/>
                    <measurement group_id="B3" value="2.31" spread="1.43"/>
                    <measurement group_id="B4" value="2.21" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Complete Spontaneous Bowel Movement (CSBM) Response</title>
        <description>This outcome measured the percentage of patients who were CSBM responders. A CSBM responder was defined as a patient with ≥3 CSBMs per week and an increase of ≥1 CSBM per week from Baseline, for at least 9 of the 12 weeks in the 12-week Treatment Period, including at least 3 weeks during Weeks 9-12.</description>
        <time_frame>During the first 12 weeks</time_frame>
        <population>Intention-to-treat (ITT) analysis set consisted of all randomized (as planned) patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Complete Spontaneous Bowel Movement (CSBM) Response</title>
          <description>This outcome measured the percentage of patients who were CSBM responders. A CSBM responder was defined as a patient with ≥3 CSBMs per week and an increase of ≥1 CSBM per week from Baseline, for at least 9 of the 12 weeks in the 12-week Treatment Period, including at least 3 weeks during Weeks 9-12.</description>
          <population>Intention-to-treat (ITT) analysis set consisted of all randomized (as planned) patients.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="23.0"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of CSBM Response</title>
        <description>This outcome measured the percentage of patients who had a CSBM within 24 hours after the first dose of treatment. A CSBM was defined as a spontaneous (occurring without laxative within the preceding 24 hours, including no rescue medication within the preceding 24 hours) bowel movement (as interpreted by the patient, with a beginning and an end, including single or multiple stools), accompanied by a patient reported sense of complete evacuation (‘complete’).</description>
        <time_frame>Within the first 24 hours of treatment initiation</time_frame>
        <population>The ITT analysis set consisted of all randomized (as planned) patients was used for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of CSBM Response</title>
          <description>This outcome measured the percentage of patients who had a CSBM within 24 hours after the first dose of treatment. A CSBM was defined as a spontaneous (occurring without laxative within the preceding 24 hours, including no rescue medication within the preceding 24 hours) bowel movement (as interpreted by the patient, with a beginning and an end, including single or multiple stools), accompanied by a patient reported sense of complete evacuation (‘complete’).</description>
          <population>The ITT analysis set consisted of all randomized (as planned) patients was used for assessment.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="24.6"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Frequency of Spontaneous Bowel Movements (SBMs)</title>
        <description>The change from Baseline for the continuous variable was estimated using a repeated measures analysis of covariance (ANCOVA) model.</description>
        <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
        <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Frequency of Spontaneous Bowel Movements (SBMs)</title>
          <description>The change from Baseline for the continuous variable was estimated using a repeated measures analysis of covariance (ANCOVA) model.</description>
          <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
          <units>SBM per week</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.64" upper_limit="2.44"/>
                    <measurement group_id="O2" value="2.44" lower_limit="2.04" upper_limit="2.84"/>
                    <measurement group_id="O3" value="1.55" lower_limit="1.15" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Stool Consistency of SBMs</title>
        <description>The stool consistency is measured using the seven-point ordinal Bristol Stool Form Scale (BSFS) score. The BSFS classifies human stool into seven types and points them accordingly.
Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid Types 1 and 2 indicate constipation, with 3 and 4 represents the ideal stool form (especially the latter), and 5, 6 and 7 tends towards diarrhoea .
For a given assessment week, the weekly stool consistency was defined as the sum of non-missing stool consistency score for SBMs during that week divided by the number of non-missing stool consistency score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
        <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
        <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Stool Consistency of SBMs</title>
          <description>The stool consistency is measured using the seven-point ordinal Bristol Stool Form Scale (BSFS) score. The BSFS classifies human stool into seven types and points them accordingly.
Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid Types 1 and 2 indicate constipation, with 3 and 4 represents the ideal stool form (especially the latter), and 5, 6 and 7 tends towards diarrhoea .
For a given assessment week, the weekly stool consistency was defined as the sum of non-missing stool consistency score for SBMs during that week divided by the number of non-missing stool consistency score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
          <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
          <units>Units on BSFS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="1.24" upper_limit="1.58"/>
                    <measurement group_id="O2" value="1.35" lower_limit="1.18" upper_limit="1.52"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.66" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Patient Assessment of Constipation – Quality of Life (PAC-QOL) Score Responder</title>
        <description>This outcome measured the percentage of patients who were PAC-QOL score responder at 12-week of Treatment Period. A PAC-QOL score responder was defined as a patient with ≥50% reduction in total PAC-QOL score from Baseline at Week 12.
PAC-QOL is a 28-item questionnaire for psychometric assessment of disease-specific quality of life. The questionnaire is based on 5-point Likert scale; ranging from 0 [none of the time or not at all] to 4 [all of the time or extremely]). A lower score indicates a better Quality of Life. The PAC-QOL questionnaire is developed specifically for patients with constipation.
Total PAC-QOL score was averaged from the individual item score.</description>
        <time_frame>At 12 weeks</time_frame>
        <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Patient Assessment of Constipation – Quality of Life (PAC-QOL) Score Responder</title>
          <description>This outcome measured the percentage of patients who were PAC-QOL score responder at 12-week of Treatment Period. A PAC-QOL score responder was defined as a patient with ≥50% reduction in total PAC-QOL score from Baseline at Week 12.
PAC-QOL is a 28-item questionnaire for psychometric assessment of disease-specific quality of life. The questionnaire is based on 5-point Likert scale; ranging from 0 [none of the time or not at all] to 4 [all of the time or extremely]). A lower score indicates a better Quality of Life. The PAC-QOL questionnaire is developed specifically for patients with constipation.
Total PAC-QOL score was averaged from the individual item score.</description>
          <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Degree of Straining of SBMs</title>
        <description>The degree of straining was measured using the five-point ordinal scale (1=Not at all, 2=A little bit, 3=A moderate amount, 4=A great deal, and 5=An extreme amount).
For a given assessment week, the weekly degree of straining was defined as the sum of non-missing straining score for SBMs during that week divided by the number of non-missing straining score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
        <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
        <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Degree of Straining of SBMs</title>
          <description>The degree of straining was measured using the five-point ordinal scale (1=Not at all, 2=A little bit, 3=A moderate amount, 4=A great deal, and 5=An extreme amount).
For a given assessment week, the weekly degree of straining was defined as the sum of non-missing straining score for SBMs during that week divided by the number of non-missing straining score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
          <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" lower_limit="-1.15" upper_limit="-0.88"/>
                    <measurement group_id="O2" value="-1.04" lower_limit="-1.17" upper_limit="-0.91"/>
                    <measurement group_id="O3" value="-0.91" lower_limit="-1.05" upper_limit="-0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Abdominal Bloating Score</title>
        <description>The abdominal bloating score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).
For a given assessment week, the weekly abdominal bloating score was defined as the sum of non-missing abdominal bloating score for SBMs during that week divided by the number of non-missing abdominal bloating score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
        <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
        <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Abdominal Bloating Score</title>
          <description>The abdominal bloating score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).
For a given assessment week, the weekly abdominal bloating score was defined as the sum of non-missing abdominal bloating score for SBMs during that week divided by the number of non-missing abdominal bloating score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
          <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" lower_limit="-0.61" upper_limit="-0.38"/>
                    <measurement group_id="O2" value="-0.52" lower_limit="-0.63" upper_limit="-0.40"/>
                    <measurement group_id="O3" value="-0.35" lower_limit="-0.47" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weekly Abdominal Discomfort Score</title>
        <description>The abdominal discomfort score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).
For a given assessment week, the weekly abdominal discomfort score was defined as the sum of non-missing abdominal discomfort score for SBMs during that week divided by the number of non-missing abdominal discomfort score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
        <time_frame>From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period</time_frame>
        <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
        <group_list>
          <group group_id="O1">
            <title>EBX 10</title>
            <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O2">
            <title>EBX 5</title>
            <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
          <group group_id="O3">
            <title>PLCBO</title>
            <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Abdominal Discomfort Score</title>
          <description>The abdominal discomfort score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).
For a given assessment week, the weekly abdominal discomfort score was defined as the sum of non-missing abdominal discomfort score for SBMs during that week divided by the number of non-missing abdominal discomfort score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.</description>
          <population>The ITT analysis set consisted of all randomized (as planned) patients.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" lower_limit="-0.54" upper_limit="-0.32"/>
                    <measurement group_id="O2" value="-0.46" lower_limit="-0.57" upper_limit="-0.35"/>
                    <measurement group_id="O3" value="-0.38" lower_limit="-0.49" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>34 weeks</time_frame>
      <desc>The Investigator monitored the condition of the patient and recorded all AEs throughout the trial from the time of obtaining informed consent until the last visit (i.e. the end of the follow-up period, as applicable) in the AEs Log . Information on AEs was collected at each trial visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>EBX 10</title>
          <description>Elobixibat 10 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
        <group group_id="E2">
          <title>EBX 5</title>
          <description>Elobixibat 5 mg/day was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
        <group group_id="E3">
          <title>PLCBO</title>
          <description>Placebo was administered orally in a tablet form starting from Baseline visit till EoT visit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the early termination of the study, outcomes were presented only for descriptive purposes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

